Phase 2 N=150 IVW-1001 Phase 1/2 in Subjects With Dry Eye Disease
Dry Eye Disease
Primary: Schirmer's — 1.3; 2.1; 0.9 mm
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=155 Baseline Oral Health Study: UnCoVer the Connections to General Health
Cardiovascular Diseases · Diabetes Type 2
Primary: Impact of Treatment on Change in Oral Health Measures — 0.186; 0.190 millimeters (probing depth difference) — p=0.957
Phase 3 N=400 A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause (OASIS-2)
Vasomotor Symptoms Associated With Menopause · Hot Flashes
Primary: Mean Change in Frequency of Moderate to Severe HF From Baseline to Week 4 (Assessed by HFDD) — 14.66; 16.16; -8.58; -6.07 Hot Flashes per day — p=< 0.0001
N/A N=79 AngioSafe Peripheral CTO Crossing System Study (RESTOR-1 Study)
Peripheral Artery Occlusion · Peripheral Arterial Disease
Primary: Clinical Success of AngioSafe Peripheral CTO Crossing System — 65 Participants
Phase 4 N=35 Counseling Among Gender Diverse Adolescents Who Use Depot Medroxyprogesterone
Gender Dysphoria, Adolescent
Primary: Number of Participants Satisfied With Self-Administered DMPA at Initiation — 17 Participants
N/A N=15 Recovery Bridge: Peer Intervention to Bridge Transition Post Discharge
Mental Illness
Primary: Feasibility 1: Recruitment Benchmark — 15 participants
N/A N=60 Efficacy of PuraSinus Versus Bioresorbable Nasal Dressings
Chronic Sinus Disease · Surgery
Primary: Pain During Debridement — 4; 5 Pain Score
Phase 3 N=165 Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
Chemotherapy-induced Thrombocytopenia
Primary: Percentage of Participants Who Had Thrombocytopenia-induced Dose Modification — 84.4; 35.7 percentage of participants — p=< 0.001
Phase 4 N=33 Study of B/F/TAF in Participants Switching From CAB + RPV to B/F/TAF for HIV-1 Infection (EMPOWER)
HIV-1-infection
Primary: Percentage of Participants Experiencing Treatment Emergent Grade 3 or 4 Drug-related Adverse Events Through Week 12 (Co-Primary Endpoint) — 0 percentage of participants
Phase 1 N=59 Food Effect Study of Brexpiprazole Once-weekly (QW) Formulation in Patients With Schizophrenia
Schizophrenia
Primary: Maximum Plasma Concentration (Cmax) of Brexpiprazole in Plasma After Administration in a Fed State Versus Administration in a Fasting State — 221.9; 365.2 ng/mL
N/A N=385 Improving Colorectal Cancer Screening in Racially Diverse Zip Codes Using Navigation and Machine Learning (PCSNaP)
Colorectal Cancer
Primary: Enrollment in Navigator Program (Feasibility) — 79 Participants
N/A N=293 Decision Making and Implementation of Aging-in-Place/Long Term Care Plans Among Older Adults
Alzheimer Disease · Mild Cognitive Impairment · Long-Term Care Planning
Primary: Rate of Participant Long Term Care Planning for Alzheimer's Dementia/Memory Loss — 173 Participants — p=.6539
Phase 4 N=154 Intubation Conditions Achieved With Rapid Co-administration of Rocuronium and Propofol Versus Classical Induction
Anesthesia
Primary: The Total Time Between Laryngoscope Insertion Into Mouth and the Onset of Ventilation After Tracheal Intubation — 30.0; 33.0 seconds
Phase 3 N=97 A Study in Adolescent and Adult Female Participants to Evaluate Clinical Symptom Improvement and the Safety of Gepotidacin During Treatment of Uncomplicated Urinary Tract Infections (Acute Cystitis)
Urinary Tract Infections
Primary: Percentage of Participants Achieving Clinical Symptom Improvement at 24 Hours (±4 Hours) — 54.4 Percentage of participants
Phase 2 N=70 The Effects of Kynurenine Aminotransferase Inhibition in People With Schizophrenia
Schizophrenia · Schizoaffective Disorder · Schizophreniform Disorder
Primary: Serum Kynurenine Levels — 2.39; 1.97; 22.0; 23.3 pmoles/ul — p=<0.05